CD8A and melanoma: Similar findings were observed using T-cell targeting 89Zr-labeled PEGylated single-domain antibody fragments (VHHs) specific for CD8+ to track the presence of intratumoral CD8+ T cells in response to CTLA-4 therapy in B16 melanoma tumor-bearing mice [19].